Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39:1972–1980

In the Research Design and Methods section of the abstract of the above-mentioned article, the value of “<5.6 mmol/mol” should read “<5.6 mmol/L.”

The online issue has been corrected to reflect this change.